Kurs
-1,16%
Kurs
-1,16%
Open
86,00
High
86,00
Low
80,40
Close
85,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
8,14 MNOK
Likviditet
8,14 MNOK
Rel. mcap
1,35%
Antal aktier
101 363
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-05-06 | N/A | Årsstämma |
2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-04-30 | - | Kvartalsrapport 2024-Q1 |
2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2024-04-29 | - | Årsstämma |
2024-02-09 | - | Bokslutskommuniké 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2023-05-04 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2022-05-18 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-21 | - | Kvartalsrapport 2021-Q3 |
2021-08-25 | - | Kvartalsrapport 2021-Q2 |
2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2021-05-04 | - | Årsstämma |
2021-04-16 | - | Kvartalsrapport 2021-Q1 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-10-29 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2020-05-14 | - | Årsstämma |
2020-04-24 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-21 | - | Extra Bolagsstämma 2019 |
2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-07-13 | - | Extra Bolagsstämma 2018 |
2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-06-06 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-10-21 08:00:00
Moss, 21 October 2021.
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the third quarter of 2021.
Highlights:
Total operating revenue of NOK 19.4 million in Q3 2021, up 20% from Q3 2020.
EBITDA was NOK -4.2 million compared to NOK -5.5 in the corresponding quarter in
2020.
Sales revenue of NOK 17.2 million, a 30% growth compared to Q3 2020. Organic
growth in Q3 2021 was 37%.
Reached final stage of negotiations of a commercial collaboration contract with
a leading global diagnostics provider for GCAL®